Serum concentrations of DKK‐1 correlate with the extent of bone disease in patients with multiple myeloma
…, R Oberländer, JRademacher… - European journal of …, 2008 - Wiley Online Library
Objectives: Lytic bone disease is a hallmark of multiple myeloma (MM) and is caused by
osteoclast activation and osteoblast inhibition. Secretion of Dickkopf (DKK)‐1 by myeloma cells …
osteoclast activation and osteoblast inhibition. Secretion of Dickkopf (DKK)‐1 by myeloma cells …
[HTML][HTML]Bronchiectasis-associated hospitalizations in Germany, 2005–2011: a population-based study of disease burden and trends
…,MW Pletz, N Hämäläinen, T Welte, JRademacher- PloS one, 2013 - journals.plos.org
Background Representative population-based data on the epidemiology of bronchiectasis
in Europe are limited. The aim of the present study was to investigate the current burden and …
in Europe are limited. The aim of the present study was to investigate the current burden and …
The EMBARC European Bronchiectasis Registry: protocol for an international observational study
…,C Haworth, W Boersma, JRademacher… - ERJ Open …, 2016 - Eur Respiratory Soc
Bronchiectasis is one of the most neglected diseases in respiratory medicine. There are no
approved therapies and few large-scale, representative epidemiological studies. The …
approved therapies and few large-scale, representative epidemiological studies. The …
Bronchiectasis in Germany: a population-based estimation of disease prevalence
…, D Hohmann, T Welte, JRademacher- European …, 2015 - Eur Respiratory Soc
健壮的evidence for the prevalence of bronchiectasis in Germany and its association with
chronic airflow obstructionhttp://ow. ly/QvSBo
chronic airflow obstructionhttp://ow. ly/QvSBo
Diffusion capacity and mortality in patients with pulmonary hypertension due to heart failure with preserved ejection fraction
MM Hoeper, K Meyer, JRademacher, J Fuge, T Welte… - JACC: Heart Failure, 2016 - jacc.org
Objectives : This study sought to investigate the prognostic importance of a low diffusion
capacity of the lung for carbon monoxide (DLCO) in patients with a catheter-based diagnosis of …
capacity of the lung for carbon monoxide (DLCO) in patients with a catheter-based diagnosis of …
The Diagnosis and Treatment of Tuberculosis.
…, SM Fünger, S Kröger, JRademacher… - Deutsches …, 2019 - search.ebscohost.com
Background: Around 10 million people worldwide contract tuberculosis every year.
According to the World Health Organization (WHO), approximately one-quarter of the world's …
According to the World Health Organization (WHO), approximately one-quarter of the world's …
The potential of proteasome inhibitors in cancer therapy
…, JC Hahne, B Lamottke, JRademacher… - Expert opinion on …, 2008 - Taylor & Francis
Background: The ubiquitin-proteasome system has become a promising novel molecular
target in cancer due to its critical role in cellular protein degradation, its interaction with cell …
target in cancer due to its critical role in cellular protein degradation, its interaction with cell …
[HTML][HTML]Prevalence of nontuberculous mycobacterial pulmonary disease, Germany, 2009–2014
…, L Hickstein, T Welte, JRademacher- Emerging infectious …, 2016 - ncbi.nlm.nih.gov
We analyzed routine statutory health insurance claim data to determine prevalence of
nontuberculous mycobacterial pulmonary disease in Germany. Documented prevalence rates of …
nontuberculous mycobacterial pulmonary disease in Germany. Documented prevalence rates of …
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma
U Heider, JRademacher, B Lamottke… - European journal of …, 2009 - Wiley Online Library
Proteasome inhibitors and histone deacetylase (HDAC) inhibitors are novel targeted therapies
being evaluated in clinical trials for cutaneous T‐cell lymphoma (CTCL). However, data in …
being evaluated in clinical trials for cutaneous T‐cell lymphoma (CTCL). However, data in …
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma
…, J Sterz, S Rötzer, JRademacher… - European journal of …, 2008 - Wiley Online Library
Objectives: Mantle cell lymphoma (MCL) is an incurable B cell lymphoma, and novel treatment
strategies are urgently needed. We evaluated the effects of combined treatment with the …
strategies are urgently needed. We evaluated the effects of combined treatment with the …